David Kramer: The first US production in 30 years of molybdenum-99, the parent isotope of the most widely used medical radioisotope, is expected to begin within weeks after federal regulators approved a manufacturing process developed by Wisconsin-based NorthStar Medical Radioisotopes. NorthStar received $25 million in matching funds from DOE for development of the neutron capture process and $14.8 million of an expected $25 million total for its accelerator approach.
IAEA, International Energy Agency, Jeremy Li: As the major research reactors that supply Mo-99 age and cease production, the alternative method discussed in the paper offers a simplified way to diversify production and help ensure continued supplies of Mo-99 so that nuclear medicine services are not interrupted. In 2009, reactors producing Mo-99 in Canada and the Netherlands were temporarily shut down for necessary repairs and maintenance. This caused major disruption in health care services worldwide, leading to cancelled medical scans and postponed operations, and in some cases requiring medical professionals to revert back to using old, less effective techniques.
IAEA, International Energy Agency: The Mo 99 supply chain will continue to remain fragile as long as it continues to rely on the same five aged production reactors. Given the way the supply chain has evolved --- particularly its reliance on only five multipurpose, non-commercial, government supported research reactors --- there are no clear market incentives to prompt new capacity or alternative supplies. No date on this document, but references indicate that it is 2009 or more recent.
Jim Ballinger - Healthcare challenges: Radioisotopes.
The clinical need: radionuclides for nuclear medicine
The problem: aging fleet of nuclear reactors, compounded by nuclear non proliferation initiatives